Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 10;6(12):3487–3495. doi: 10.1002/hep4.2103

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Dynamic changes between the FF group and the UDCA group at each follow‐up visit. (A) Alkaline phosphatase, (B) total bilirubin, (C) UK‐PBC risk score, (D) alanine aminotransferase, (E) aspartate aminotransferase, (F) triglyceride, (G), cholesterol, (H) APRI score, (I) FIB‐4 index, (J) serum creatinine, (K) blood urea, and (L) estimated glomerular filtration rate. Shown are the median values and interquartile ranges. Data were compared by the Mann‐Whitney U test. APRI, aspartate aminotransferase‐to‐platelet ratio index; FF, fenofibrate; FIB‐4, fibrosis‐4; LLN, lower limit of normal; NS, not significant; UDCA, ursodeoxycholic acid; UK‐PBC, United Kingdom primary biliary cholangitis; ULN, upper limit of normal.